Purpose: To identify the correlation between near work and the occurrence of delayed-onset consecutive esotropia after surgery for intermittent exotropia. Methods: A survey and retrospective review were conducted on patients in two groups. The study included patients who visited from January 2019 to January 2020. Patients who re-developed esodeviation after recovering orthophoria after the initial postoperative overcorrection for the surgical correction of intermittent exotropia were included in the delayed-onset esotropia group (Group 1), and patients with persistent orthotropia for at least 3 years after bilateral lateral rectus recession for intermittent exotropia were included in Group 2. We evaluated the daily frequency and hours of distanceear work in both groups. Results: A total of 42 patients were evaluated. Preoperative exodeviation at a distance was 28.5 ± 4.4 prism diopters (PD) in group 1 and 30.5 ± 5.2 PD in group 2, with no significant difference between the two groups. The percentages of patients who chose two or more extremely near-work activities a day were 47.8% and 15.8% for groups 1 and 2, respectively; these values were statistically significant (p = 0.02). Twelve patients in Group 2 answered “watching TV” (63.2%) as the most common activity, which was statistically significant compared to Group 1 (26.1% in Group 1, p = 0.02). The total numbers of hours of extremely near-work a day were 2.7 ± 2.1 and 1.5 ± 1.2 hours for groups 1 and 2, respectively, which was also statistically significant (p = 0.037). Conclusions We found a significant correlation with occurrence of delayed-onset consecutive esotropia with the frequency and hours of extremely near-work after bilateral lateral rectus recession for intermittent exotropia. More attention to extremely near-work should be considered carefully after bilateral lateral rectus recession for intermittent exotropia.

Purpose: To identify the correlation between near work and the occurrence of delayed-onset consecutive esotropia after surgery for intermittent exotropia. Methods: A survey and retrospective review were conducted on patients in two groups. The study included patients who visited from January 2019 to January 2020. Patients who re-developed esodeviation after recovering orthophoria after the initial postoperative overcorrection for the surgical correction of intermittent exotropia were included in the delayed-onset esotropia group (Group 1), and patients with persistent orthotropia for at least 3 years after bilateral lateral rectus recession for intermittent exotropia were included in Group 2. We evaluated the daily frequency and hours of distanceear work in both groups. Results: A total of 42 patients were evaluated. Preoperative exodeviation at a distance was 28.5 ± 4.4 prism diopters (PD) in group 1 and 30.5 ± 5.2 PD in group 2, with no significant difference between the two groups. The percentages of patients who chose two or more extremely near-work activities a day were 47.8% and 15.8% for groups 1 and 2, respectively; these values were statistically significant (p = 0.02). Twelve patients in Group 2 answered “watching TV” (63.2%) as the most common activity, which was statistically significant compared to Group 1 (26.1% in Group 1, p = 0.02). The total numbers of hours of extremely near-work a day were 2.7 ± 2.1 and 1.5 ± 1.2 hours for groups 1 and 2, respectively, which was also statistically significant (p = 0.037). Conclusions We found a significant correlation with occurrence of delayed-onset consecutive esotropia with the frequency and hours of extremely near-work after bilateral lateral rectus recession for intermittent exotropia. More attention to extremely near-work should be considered carefully after bilateral lateral rectus recession for intermittent exotropia.

Purpose: To compare the myopic progression between pateints only wearing glasses (Myopia group) and patients using low-dose atropine with glasses (Atropine group) for 1 years or more. Methods: Medical records were retrospectively reviewed. Low-dose atropine (atropine sulfate 0.125%) and artificial tear eyedrops (sodium hyaluronate 0.1%) were applied immediately afterwards to both eyes daily to the Atropine group. All children regularly visited our clinic for measurement of refractive power, axial length, near-point accomodation, pupil diameter, symptoms (glare, near-work disturbance, headache, allergic reaction, dryness) were recorded. Results: A total of 240 patients were included. Atropine was prescribed for 138 patients, the Atropine group, and the remaining 102 patients constituted the Myopia group, and were observed for 20.3 ± 7.8 months. In the initial visit, the mean refractive power was -4.2 ± 1.4 diopters (D) for the Myopia group, -4.8 ± 1.9 D for the Atropine group, and the mean axial length was 24.5 ± 0.6 mm for the Myopia group, 25.1 ± 0.9 mm for the Atropine group. During follow up, in the Myopia group, mean refractive power changed -0.10 ± 0.12 D/month, and mean axial length changed 0.06 ± 0.01 mm/month. In the Atropine group, mean refractive power changed -0.03 ± 0.04 D/month, and mean axial length changed 0.02 ± 0.02 mm/month. The pupil size of the Atropine group was 6.1 ± 0.8 mm, with 30 patients presenting symptoms. Conclusions Refractive power progression and axial length elongation was significantly lesser in the Atropine group than the Myopic group. Pupil diameter increased in the Atropine group, and 21% of the Atropine group complained of symptoms. Using low-dose atropine for more than 1 year was effective to suppress refractive power progression and axial length elongation.

Purpose: To compare the myopic progression between pateints only wearing glasses (Myopia group) and patients using low-dose atropine with glasses (Atropine group) for 1 years or more. Methods: Medical records were retrospectively reviewed. Low-dose atropine (atropine sulfate 0.125%) and artificial tear eyedrops (sodium hyaluronate 0.1%) were applied immediately afterwards to both eyes daily to the Atropine group. All children regularly visited our clinic for measurement of refractive power, axial length, near-point accomodation, pupil diameter, symptoms (glare, near-work disturbance, headache, allergic reaction, dryness) were recorded. Results: A total of 240 patients were included. Atropine was prescribed for 138 patients, the Atropine group, and the remaining 102 patients constituted the Myopia group, and were observed for 20.3 ± 7.8 months. In the initial visit, the mean refractive power was -4.2 ± 1.4 diopters (D) for the Myopia group, -4.8 ± 1.9 D for the Atropine group, and the mean axial length was 24.5 ± 0.6 mm for the Myopia group, 25.1 ± 0.9 mm for the Atropine group. During follow up, in the Myopia group, mean refractive power changed -0.10 ± 0.12 D/month, and mean axial length changed 0.06 ± 0.01 mm/month. In the Atropine group, mean refractive power changed -0.03 ± 0.04 D/month, and mean axial length changed 0.02 ± 0.02 mm/month. The pupil size of the Atropine group was 6.1 ± 0.8 mm, with 30 patients presenting symptoms. Conclusions Refractive power progression and axial length elongation was significantly lesser in the Atropine group than the Myopic group. Pupil diameter increased in the Atropine group, and 21% of the Atropine group complained of symptoms. Using low-dose atropine for more than 1 year was effective to suppress refractive power progression and axial length elongation.

Purpose: To compare the myopic progression between pateints only wearing glasses (Myopia group) and patients using low-dose atropine with glasses (Atropine group) for 1 years or more. Methods: Medical records were retrospectively reviewed. Low-dose atropine (atropine sulfate 0.125%) and artificial tear eyedrops (sodium hyaluronate 0.1%) were applied immediately afterwards to both eyes daily to the Atropine group. All children regularly visited our clinic for measurement of refractive power, axial length, near-point accomodation, pupil diameter, symptoms (glare, near-work disturbance, headache, allergic reaction, dryness) were recorded. Results: A total of 240 patients were included. Atropine was prescribed for 138 patients, the Atropine group, and the remaining 102 patients constituted the Myopia group, and were observed for 20.3 ± 7.8 months. In the initial visit, the mean refractive power was -4.2 ± 1.4 diopters (D) for the Myopia group, -4.8 ± 1.9 D for the Atropine group, and the mean axial length was 24.5 ± 0.6 mm for the Myopia group, 25.1 ± 0.9 mm for the Atropine group. During follow up, in the Myopia group, mean refractive power changed -0.10 ± 0.12 D/month, and mean axial length changed 0.06 ± 0.01 mm/month. In the Atropine group, mean refractive power changed -0.03 ± 0.04 D/month, and mean axial length changed 0.02 ± 0.02 mm/month. The pupil size of the Atropine group was 6.1 ± 0.8 mm, with 30 patients presenting symptoms. Conclusions Refractive power progression and axial length elongation was significantly lesser in the Atropine group than the Myopic group. Pupil diameter increased in the Atropine group, and 21% of the Atropine group complained of symptoms. Using low-dose atropine for more than 1 year was effective to suppress refractive power progression and axial length elongation.

Purpose: To compare the myopic progression between pateints only wearing glasses (Myopia group) and patients using low-dose atropine with glasses (Atropine group) for 1 years or more. Methods: Medical records were retrospectively reviewed. Low-dose atropine (atropine sulfate 0.125%) and artificial tear eyedrops (sodium hyaluronate 0.1%) were applied immediately afterwards to both eyes daily to the Atropine group. All children regularly visited our clinic for measurement of refractive power, axial length, near-point accomodation, pupil diameter, symptoms (glare, near-work disturbance, headache, allergic reaction, dryness) were recorded. Results: A total of 240 patients were included. Atropine was prescribed for 138 patients, the Atropine group, and the remaining 102 patients constituted the Myopia group, and were observed for 20.3 ± 7.8 months. In the initial visit, the mean refractive power was -4.2 ± 1.4 diopters (D) for the Myopia group, -4.8 ± 1.9 D for the Atropine group, and the mean axial length was 24.5 ± 0.6 mm for the Myopia group, 25.1 ± 0.9 mm for the Atropine group. During follow up, in the Myopia group, mean refractive power changed -0.10 ± 0.12 D/month, and mean axial length changed 0.06 ± 0.01 mm/month. In the Atropine group, mean refractive power changed -0.03 ± 0.04 D/month, and mean axial length changed 0.02 ± 0.02 mm/month. The pupil size of the Atropine group was 6.1 ± 0.8 mm, with 30 patients presenting symptoms. Conclusions Refractive power progression and axial length elongation was significantly lesser in the Atropine group than the Myopic group. Pupil diameter increased in the Atropine group, and 21% of the Atropine group complained of symptoms. Using low-dose atropine for more than 1 year was effective to suppress refractive power progression and axial length elongation.

PURPOSE: Combined chemoradiotherapy is standard management for locally advanced non-small cell lung cancer (LA-NSCLC), but standard treatment for elderly patients with LA-NSCLC has not been confirmed yet. We evaluated the feasibility and efficacy of concurrent chemoradiotherapy (CCRT) for elderly patients with LA-NSCLC. MATERIALS AND METHODS: Among patients older than 65 years with LA-NSCLC, 36 patients, who underwent CCRT were retrospectively analyzed. Chemotherapy was administered 3-5 times with 4 weeks interval during radiotherapy. Thoracic radiotherapy was delivered to the primary mass and regional lymph nodes. Total dose of 54-59.4 Gy (median, 59.4 Gy) in daily 1.8 Gy fractions and 5 fractions per week. RESULTS: Regarding the response to treatment, complete response, partial response, and no response were shown in 16.7%, 66.7%, and 13.9%, respectively. The 1- and 2-year overall survival (OS) rates were 58.2% and 31.2%, respectively, and the median survival was 15 months. The 1- and 2-year progression-free survivals (PFS) were 41.2% and 19.5%, respectively, and the median PFS was 10 months. Regarding to the toxicity developed after CCRT, pneumonitis and esophagitis with grade 3 or higher were observed in 13.9% (5 patients) and 11.1% (4 patients), respectively. Treatment-related death was not observed. CONCLUSION: The treatment-related toxicity as esophagitis and pneumonitis were noticeably lower when was compared with the previously reported results, and the survival rate was higher than radiotherapy alone. The results indicate that CCRT is an effective in terms of survival and treatment related toxicity for elderly patients over 65 years old with LA-NSCLC.
Aged ; Carcinoma, Non-Small-Cell Lung ; Chemoradiotherapy ; Disease-Free Survival ; Esophagitis ; Humans ; Lymph Nodes ; Pneumonia ; Retrospective Studies ; Survival Rate

Neuroleptic malignant syndrome (NMS) is a rare but potentially lethal outcome caused by sudden discontinuation or dose reduction of dopaminergic agents. We report an extremely rare case of NMS after deep brain stimulation (DBS) surgery in a cerebral palsy (CP) patient without the withdrawal of dopaminergic agents. A 19-year-old girl with CP was admitted for DBS due to medically refractory dystonia and rigidity. Dopaminergic agents were not stopped preoperatively. DBS was performed uneventfully under monitored anesthesia. Dopaminergic medication was continued during the postoperative period. She manifested spasticity and muscle rigidity, and was high fever resistant to anti-pyretic drugs at 2 h postoperative. At postoperative 20 h, she suffered cardiac arrest and expired, despite vigorous cardiopulmonary resuscitation. NMS should be considered for hyperthermia and severe spasticity in CP patients after DBS surgery, irrespective of continued dopaminergic medication.
Anesthesia ; Cardiopulmonary Resuscitation ; Cerebral Palsy* ; Deep Brain Stimulation* ; Dopamine Agents ; Dystonia ; Female ; Fever ; Globus Pallidus* ; Heart Arrest ; Humans ; Muscle Rigidity ; Muscle Spasticity ; Neuroleptic Malignant Syndrome ; Postoperative Period ; Young Adult

In 1912, Crouzon reported one of craniofacial dysostosis, which was inherited as an autosomal dominant trait and characterized by craniosynostosis, midface hypoplasia, and exorbitism. In 1950, the first midface advancement was performed by means of a total facial osteotomy by Sir Harold Gillies. In 1967, Tessier accomplished complete craniofacial dysjunction by performing Le Fort III-Tessier I osteotomy on the basis of Le Fort III fracture and laid the foundation for modern craniofacial surgery. Variable combinations of the surgeries and osteotomies are performed considering functional disabilities as well as patient's age, general condition, and aesthetic problems. The nineteen-year-old female patient complained of frog-like face and showed severe exorbitism and midface hypoplasia, while the occlusion, being relatively normal. We applied modified Le Fort III osteotomy and fronto- orbital advancement. Over the follow-up period of six months, her previous normal occlusion was preserved and the exorbitism and midface deformity largely improved aesthetically.
Congenital Abnormalities ; Craniofacial Dysostosis* ; Craniosynostoses ; Female ; Follow-Up Studies ; Humans ; Orbit ; Osteotomy*

Osteoma of the paranasal sinus is benign tumor, and it is mostly located in frontal and ethmoid sinus, produces symptoms of headache, nasal obstruction and ocular complication of exophthalmos, ocular pain, restricted ocular motility, and diplopia. Recently the authors have experienced one case of osteoma of ethmoidal sinus which could be removed by external ethmoidectomy.
Diplopia ; Ethmoid Sinus* ; Exophthalmos* ; Headache ; Nasal Obstruction ; Osteoma*